SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3558 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2582I am not a finance person, what does this mean?!?!?!Felix B-11/14/2018
2581Oh, no! SELF! sec.govMiljenko Zuanic-11/14/2018
2580It is not that REGN IP is bad (except praluent case), it is that other-competitoMiljenko Zuanic-11/8/2018
2579I was being a bit sarcastic. "Damning with faint praise," as the sayituck-11/8/2018
2578Is REGN IP that bad? Surprised this did not come up during the call or more preFelix B-11/7/2018
2577Praluent CVOT, at NEJM finance.yahoo.comMiljenko Zuanic-11/7/2018
2576Anti-IL33, REGN3500 Dose in Asthma trial is ????, regimen SC Q2W! clinicaltriaMiljenko Zuanic-11/7/2018
2575*Well, at least their scientists can tell the business development team what to Miljenko Zuanic-11/7/2018
2574Correct, in whole picture it may not be an issue at all! They need to move 2810Miljenko Zuanic-11/7/2018
2573Anyway, looks like REGN will pay ROYALTY on any and every their candidate! How ttuck-11/7/2018
2572The 8% (pre-tax) royalty equates to about 6% after-tax. Moreover, this rate is fDewDiligence_on_SI-11/7/2018
2571< Does anyone here see material sales for Libtayo?> IF Libtayo sale can nMiljenko Zuanic-11/7/2018
2570Projection for 4Q Libtayo (I hate this name) sale is $3-5M, and for 1Q-19 +$5M. Miljenko Zuanic-11/7/2018
2569An 8% royalty on nothing comes to…nothing. Does anyone here see material sales fDewDiligence_on_SI-11/7/2018
2568Another input from 10Q: -8% Libtayo royalty to BMY/Ono Marketed Products - AddiMiljenko Zuanic211/7/2018
25673Q report tid-bits: -Regn's losses in connection with Sanofi's collaboraMiljenko Zuanic-11/7/2018
2566They wasted 40 min on prepared remarks. They can post Prep.R. on web-page, have Miljenko Zuanic-11/6/2018
2565What exactly do you not like about it? I do think they should spend more time oFelix B-11/6/2018
2564On Q about future Eylea market dynamic, Schleifer mentioned continuous 10-15% grMiljenko Zuanic111/6/2018
2563<Every time I listen to REGN cc, I develop instant *vomiting*!> Why they Miljenko Zuanic-11/6/2018
2562Eylea US sale were as predicted ($2020M), while ex-US were lower than predicted Miljenko Zuanic-11/6/2018
2561Every time I listen to REGN cc, I develop instant *vomiting*!Miljenko Zuanic-11/6/2018
2560Thanks Tuck. REGN has GITR agonist-Abs from 2016 (provisional application), but Miljenko Zuanic-11/2/2018
2559GITR programs: This paper, in table 2, details the compounds in development as otuck-11/2/2018
2558Again, to repeat here something that is *EXTRA NON-ORDINARY* for EYLEA: pmprb-cMiljenko Zuanic-11/2/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News